Emerging Stock Report Initiates Independent Research Coverage on Inovio Biomed Corp

CALGARY, Alberta, Nov. 20, 2009 (GLOBE NEWSWIRE) -- Emerging Stock Report, a leading provider of sector specific independent investment research, today initiated coverage on Inovio Biomed Corp (NYSE Amex: INO). Emerging Stock Report is currently offering a complimentary trial subscription to the investment community.

To view the Report in its entirety visit: http://www.emergingstockreport.com

To get our alerts AHEAD of the market follow us on Twitter: http://twitter.com/EmergingStockRe

About ESR:

Emerging Stock Report is a leading provider of independent investment research for North American companies. Our services include research analysis on emerging growth companies, sector specific research, real-time news and financial data, market commentary and the ESR newsletter. Emerging Stock Report's staff of investment professionals are dedicated to providing the the tools and resources necessary to help make important investment decisions. To view our research reports on a complimentary trial basis and take advantage of our other services, visit http://www.emergingstockreport.com and click on the complimentary trial subscription button on our home page, or go directly to our registration page at http://emergingstockreport.com/register.php

About INOVIO BIOMED CORP:

Conventional influenza vaccines can only provide protection if they substantially match the genetic makeup of the circulating virus strain(s). They have limited ability to protect against genetic shifts of the virus. As a result, a new vaccine is created each year in anticipation of the next flu season's new strain(s). If a significantly different new strain emerges, such as the current swine-origin pandemic strain, then the current vaccine will provide little or no protective capability.

Inovio is developing DNA-based influenza vaccines intended to provide broad protection against known as well as newly emerging, unknown seasonal and pandemic influenza strains. Using its SynCon process, Inovio's scientists designed DNA constructs representing an optimal consensus of HA, NA, and NP proteins derived from multiple strains of the sub-types H1N1, H2N2, H3N2, and H5N1. These virus sub-types have been responsible for the majority of the last century's seasonal and pandemic influenza outbreaks. Animal data is showing that Inovio's synthetically-derived consensus DNA constructs, which do not match specific influenza strains, provide protection against viruses sharing genetic roots within sub-types. By formulating a single vaccine with constructs from some or all of the key sub-types, protection may be achieved against seasonal as well as pandemic strains such as swine flu or pandemic-potential strains such as avian influenza.

ESR Disclosure:

Emerging Stock Report is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. Emerging Stock Report has not been compensated by any of the above mentioned companies. Please read our report and visit our Web site, http://www.EmergingStockReport.com, for complete risks and disclosures.

CONTACT:  Emerging Stock Report
          Dylan Anderson
          1 (206) 905-9680
          info@emergingstockreport.com